FDA Approves New F8 Formulation of Tesamorelin for HIV Lipodystrophy
The FDA approved a new formulation of tesamorelin, the only approved treatment for HIV-associated excess abdominal fat, representing continued investment in peptide therapeutics for rare conditions.